Drug profile · INN
olaratumab
LARTRUVO
olaratumab (LARTRUVO) is a platelet-derived growth factor receptor alpha antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — olaratumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
olaratumab (LARTRUVO) is a platelet-derived growth factor receptor alpha antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Platelet-derived growth factor receptor alpha antagonist
Primary target: Platelet-derived growth factor receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is olaratumab?
olaratumab (LARTRUVO) is a platelet-derived growth factor receptor alpha antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for olaratumab?
LARTRUVO is a marketed brand name for olaratumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olaratumab?
olaratumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.